Current first-line therapies like allopurinol and febuxostat can be very effective, but some patients – roughly 1% according to FDA estimates – don’t get the hoped-for benefit, while others ...

6 AP-HP, Dèpartement d'Epidèmiologie et Recherche Clinique, Hôpital Bichat, Paris, France: APHP, Centre de Pharmacoèpidèmiologie, Paris, France: Univ Paris ...